Aerska, a biotechnology company focused on developing therapies for neurodegenerative diseases, has announced that it has raised $39 million in funding.

The company's primary goal is to develop innovative technologies that enable RNA-based drugs to effectively reach the brain, overcoming the blood-brain barrier. This barrier represents a significant challenge in the development of treatments for diseases such as Alzheimer's and Parkinson's, as it prevents many drugs from reaching brain tissue in therapeutic concentrations.

The funding will be used to further develop Aerska's technology platforms and advance its preclinical programs. The company aims to improve drug delivery and develop more effective therapies for patients suffering from these debilitating conditions.

Neurodegenerative diseases represent a growing challenge for public health, with a significant impact on the quality of life of patients and their families. The search for new therapies is therefore of fundamental importance.